Emerging studies suggest this peptide, a dual agonist targeting both incretin and another hormone, appears to provide a promising advancement for body loss . Initial human trials have indicated considerable decreases in body tissue, potentially exceeding current obesity medications . Nevertheless , further assessment is necessary to thoroughly unde